BioMarin Pharmaceutical Inc. (BMRN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
BioMarin Pharmaceutical Inc. (BMRN) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How BMRN Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $3.22B | 77.7% | 12.7% | $348.9M | $725.0M | 6% |
| FY 2024 | $2.85B | 79.7% | 17% | $426.9M | $487.4M | 7.2% |
| FY 2023 | $2.42B | 44% | 7.7% | $167.6M | $50.4M | 4% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring BMRN)
- ✓Live walkthrough of BMRN's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
BMRN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +12.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BMRN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BMRN. Explore sector supply chains on /butterfly.
BMRN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is BioMarin Pharmaceutical Inc. (BMRN)?
In FY 2025 (10-K), BMRN converted $3.2B of revenue into a 77.7% gross margin, 12.7% operating margin, and $725.0M in free cash flow (22.5% FCF margin).